Immunotherapy in lung cancer

Survival rates for metastatic lung cancer including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are poor with 5-year survival of less than 5%. The use of molecular targeted therapies has improved median overall survival (OS) in a limited group of NSCLC patients whose tumors...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Lung Cancer Res
Main Authors: Massarelli, Erminia, Papadimitrakopoulou, Vassiliki, Welsh, James, Tang, Chad, Tsao, Anne S.
Format: Artigo
Jezik:Inglês
Izdano: Pioneer Bioscience Publishing Company 2014
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367607/
https://ncbi.nlm.nih.gov/pubmed/25806281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.01.01
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki